- 中
- 繁
- EN
Beijing, Shanghai, Boston - Jacobio Pharma (1167.HK) announced the appointment of Dr. Alan Xiao as the company's Vice President of Clinical Pharmacology, who will be based in Boston and lead the Clinical Pharmacology team at Jacobio.
"Dr. Alan Xiao will bring extensive experience in clinical pharmacology research, helping Jacobio Pharma in the global development of its projects. He will further enhance the company's R&D capabilities. We welcome his joining." said Dr. Yinxiang Wang, Chairman and CEO of Jacobio Pharma. Dr. Alan Xiao has over 20 years of experience in drug development.
Dr. Alan Xiao obtained his Ph.D. from Rice University, US, and then conducted professional training in clinical pharmacology, advanced pharmacokinetics, and pharmacodynamics at the State University of New York at Buffalo. Prior to working for Jacobio, he worked for many multinational pharmaceutical companies such as Novartis, AstraZeneca, and Merck, and has held management positions in many biotech companies, leading the company's clinical pharmacology capability development.
Dr. Alan Xiao said: "I am honored to join Jacobio Pharma, and I look forward to working with the team to develop promising pipelines."
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.
Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD. Beijing ICP B 17065868-1 
京公网安备 11030102011242号